section name header

Pronunciation

REV-e-fen-a-sin

Classifications

Therapeutic Classification: bronchodilators

Pharmacologic Classification: anticholinergics

Indications

REMS


Action

  • Acts as an anticholinergic by inhibiting the M3 receptor in bronchial smooth muscle, which leads to bronchodilation.
Therapeutic effects:
  • Bronchodilation with lessened symptoms of COPD.

Pharmacokinetics

Absorption: 3% systemically absorbed following oral inhalation.

Distribution: Extensively distributed to tissues.

Metabolism/Excretion: Rapidly hydrolyzed to an active metabolite. Primarily eliminated in feces (88%) with less than 5% excreted in urine.

Half-Life: 22–70 hr.

Time/Action Profile

(plasma concentrations)

ROUTEONSETPEAKDURATION
Nebulizationrapid14–41 min24 hr





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Interactions

Drug-drug:

Route/Dosage

Availability

Assessment

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Yupelri